FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Pieter Van Doorn

Research Profile

Disorders

Chemicals & Drugs

Living Beings

Campylobacter jejuni

Concepts & Ideas

Procedures

Physiology

Disease Progression

Geographic Areas

Netherlands

Co-author Network

Publications

TOP 3
Bianca van den Berg; Pieter A Van Doorn; Carina Bunschoten; Bart C Jacobs
Mortality in Guillain-Barre syndrome.
N A M E van der Beek; Ans T Van Der Ploeg; Pieter A Van Doorn; M L C Hagemans; I S J Merkies
The Rasch-built Pompe-specific activity (R-PAct) scale.
Stephan C A Wens; Mark G J M Wijgerde; Ans T Van Der Ploeg; Pieter A Van Doorn; Juna M de Vries; Marianne Hoogeveen-Westerveld; Marian A Kroos; Arnold J J Reuser
Remarkably low fibroblast acid α-glucosidase activity in three adults with Pompe disease.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Pieter Van Doorn (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Bianca van den Berg; Pieter A Van Doorn; Carina Bunschoten; Bart C Jacobs
Mortality in Guillain-Barre syndrome.
Neurology 2013;80(18):1650-4.
2013: N A M E van der Beek; Ans T Van Der Ploeg; Pieter A Van Doorn; M L C Hagemans; I S J Merkies
The Rasch-built Pompe-specific activity (R-PAct) scale.
Neuromuscular disorders : NMD 2013;23(3):256-64.
2012: Stephan C A Wens; Mark G J M Wijgerde; Ans T Van Der Ploeg; Pieter A Van Doorn; Juna M de Vries; Marianne Hoogeveen-Westerveld; Marian A Kroos; Arnold J J Reuser
Remarkably low fibroblast acid α-glucosidase activity in three adults with Pompe disease.
Molecular genetics and metabolism 2012;107(3):485-9.
2012: Els Karla Vanhoutte; Hendrik Boot; Elisabeth Aviva Cats; David R Cornblath; Jeroen Engelsman; Marijke Eurelings; Catharina Gerritdina Faber; Kenneth C Gorson; Mieke Catharina Elisabeth Hermans; Bart Casper Jacobs; Giuseppe Lauria; Ronaldus Jacobus Meijer; I S J Merkies; Nicolette C Notermans; Alan Tennant; Leonard Hendrik van den Berg; Nadine Anna Maria Elisabeth van der Beek; Anneke J van der Kooi; W-Ludo van der Pol; Pieter A Van Doorn; Rinske van Koningsveld; Sonja Ingrid van Nes
Modifying the Medical Research Council grading system through Rasch analyses.
Brain : a journal of neurology 2012;135(Pt 5):1639-49.
2012: C M van Gelder; Pieter A Van Doorn; I F M de Coo; Henriëtte H W de Gier; B J Ebbink; Marieke M Hakkesteegt; I Moor-van Nugteren; Arnold J J Reuser; C I van Capelle; Johanna M P Van den Hout; Ans T Van Der Ploeg
Facial-muscle weakness, speech disorders and dysphagia are common in patients with classic infantile Pompe disease treated with enzyme therapy.
Journal of inherited metabolic disease 2012;35(3):505-11.
2012: F Eftimov; Pieter A Van Doorn; Ivo van Schaik; Marinus Vermeulen; Esther Brusse
Long-term remission of CIDP after pulsed dexamethasone or short-term prednisolone treatment.
Neurology 2012;78(14):1079-84.
2012: Nadine A M E van der Beek; Ans T Van Der Ploeg; Pieter A Van Doorn; Hans Verschuure; Arnold J J Reuser; René M L Poublon
Hearing in adults with Pompe disease.
Journal of inherited metabolic disease 2012;35(2):335-41.
2012: Carine I van Capelle; Nadine A M E van der Beek; Pieter A Van Doorn; Juna M de Vries; Hugo J Duivenvoorden; M L C Hagemans; Robert T Leshner; Ans T Van Der Ploeg
The quick motor function test: a new tool to rate clinical severity and motor function in Pompe patients.
Journal of inherited metabolic disease 2012;35(2):317-23.
2012: Liselotte Ruts; Joke H M Tulen; Anton H van den Meiracker; Pieter A Van Doorn; Elize D Haasdijk; Roelie J Hempel; Raffaella Lombardi; Paola Penza; Giuseppe Lauria
Unmyelinated and myelinated skin nerve damage in Guillain-Barré syndrome: correlation with pain and recovery.
Pain 2012;153(2):399-409.
2012: Nadine A M E van der Beek; Anneke J van der Kooi; Ans T Van Der Ploeg; Baziel G M van Engelen; Jan J G M Verschuuren; John H J Wokke; Marianne De Visser; Juna M de Vries; Karin G Faber; M L C Hagemans; Wim C J Hop; Marian A Kroos; Jan B M Kuks; Nicolette C Notermans; Arnold J J Reuser; Pieter A Van Doorn
Clinical features and predictors for disease natural progression in adults with Pompe disease: a nationwide prospective observational study.
Orphanet journal of rare diseases 2012;7():88.
2012: Juna M de Vries; Catharina G Faber; Wim C J Hop; Francois P J Karstens; Michelle E Kruijshaar; Jan B M Kuks; Nicolette C Notermans; Arnold J J Reuser; Nadine A M E van der Beek; Anneke J van der Kooi; Pieter A Van Doorn; Baziel G M van Engelen; Jan J G M Verschuuren; John H Wokke; Marianne De Visser; Ans T Van Der Ploeg
Effect of enzyme therapy and prognostic factors in 69 adults with Pompe disease: an open-label single-center study.
Orphanet journal of rare diseases 2012;7():73.
2011: Juna M de Vries; Lale Ozkan; Arnold J J Reuser; Eric A P Steegers; Jan-Dietert C Brugma; Pieter A Van Doorn; Ans T Van Der Ploeg
First experience with enzyme replacement therapy during pregnancy and lactation in Pompe disease.
Molecular genetics and metabolism 2011;104(4):552-5.
2011: N A M E van der Beek; Ans T Van Der Ploeg; K I van der Velden-van Etten; Pieter A Van Doorn; W C J Hop; Arnold J J Reuser; C I van Capelle; B van den Berg; H Stam
Rate of progression and predictive factors for pulmonary outcome in children and adults with Pompe disease.
Molecular genetics and metabolism 2011;104(1-2):129-36.
2011: Martine E Bos Eyssen; Peter H J van der Voort; Pieter A Van Doorn; Durk F Zandstra; Jan Bakker; Cornelia W Hoedemaekers; Janneke Horn; Bart C Jacobs; Peter E Spronk; Ewout W Steyerberg; Mathieu van der Jagt
Selective digestive tract decontamination decreases time on ventilator in Guillain-Barré syndrome.
Neurocritical care 2011;15(1):128-33.
2011: Pieter A Van Doorn; Krista Kuitwaard; Bart C Jacobs
Serum IgG levels as biomarkers for optimizing IVIg therapy in CIDP.
Journal of the peripheral nervous system : JPNS 2011;16 Suppl 1():38-40.
2011: Jeroen J J van Eijk; Baziel G M van Engelen; Paul Herbrink; Marijke Maas; Ruben P Portier; Anne P Tio-Gillen; Nens van Alfen; Pieter A Van Doorn; Bart C Jacobs
Screening for antecedent Campylobacter jejuni infections and anti-ganglioside antibodies in idiopathic neuralgic amyotrophy.
Journal of the peripheral nervous system : JPNS 2011;16(2):153-6.
2011: Dirk C G Straver; Leonard H Van den Berg; Pieter A Van Doorn; Hessel Franssen
Symptoms of activity-induced weakness in peripheral nervous system disorders.
Journal of the peripheral nervous system : JPNS 2011;16(2):108-12.
2011: Maaike M van der Graaff; Caroline A Sage; Matthan W A Caan; Erik M Akkerman; Cristina Lavini; Charles B L M Majoie; Aart J Nederveen; Aeilko H Zwinderman; Frans M Vos; Frans Brugman; Leonard H Van den Berg; Maarten C de Rijk; Pieter A Van Doorn; Wim Van Hecke; Ronald Peeters; Wim Robberecht; Stefan Sunaert; Marianne De Visser
Upper and extra-motoneuron involvement in early motoneuron disease: a diffusion tensor imaging study.
Brain : a journal of neurology 2011;134(Pt 4):1211-28.
2011: C Walgaard; Hester Floor Lingsma; Liselotte Ruts; Pieter A Van Doorn; Ewout W Steyerberg; Bart C Jacobs
Early recognition of poor prognosis in Guillain-Barre syndrome.
Neurology 2011;76(11):968-75.
2011: Judith Drenthen; Nobuhiro Yuki; Jan Meulstee; Ellen M Maathuis; Pieter A Van Doorn; Gerhard H Visser; Joleen H Blok; Bart C Jacobs
Guillain-Barré syndrome subtypes related to Campylobacter infection.
Journal of neurology, neurosurgery, and psychiatry 2011;82(3):300-5.
2011: Linda E M van den Berg; Juna M de Vries; Robert M Verdijk; Ans T Van Der Ploeg; Arnold J J Reuser; Pieter A Van Doorn
A case of adult Pompe disease presenting with severe fatigue and selective involvement of type 1 muscle fibers.
Neuromuscular disorders : NMD 2011;21(3):232-4.
2011: S I van Nes; E K Vanhoutte; Pieter A Van Doorn; M Hermans; M Bakkers; K Kuitwaard; C G Faber; I S J Merkies
Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies.
Neurology 2011;76(4):337-45.
2011: Deniz Güngör; Juna M de Vries; Wim C J Hop; Arnold J J Reuser; Ans T van der Ploeg; Pieter A Van Doorn; Marloes L C Hagemans
Survival and associated factors in 268 adults with Pompe disease prior to treatment with enzyme replacement therapy.
Orphanet journal of rare diseases 2011;6():34.
2010: Juna M de Vries; Nadine A M E van der Beek; Marian A Kroos; Lale Ozkan; Pieter A Van Doorn; Susan M Richards; Crystal C C Sung; Jan-Dietert C Brugma; Adrienne A M Zandbergen; Ans T Van Der Ploeg; Arnold J J Reuser
High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa.
Molecular genetics and metabolism 2010;101(4):338-45.
2010: K Kuitwaard; Leonard H Van den Berg; Marinus Vermeulen; Esther Brusse; E A Cats; Alexander van der Kooi; N C Notermans; W-L van der Pol; Ivo van Schaik; S I van Nes; W C J Hop; Pieter A Van Doorn
Randomised controlled trial comparing two different intravenous immunoglobulins in chronic inflammatory demyelinating polyradiculoneuropathy.
Journal of neurology, neurosurgery, and psychiatry 2010;81(12):1374-9.
2010: Liselotte Ruts; J Drenthen; J L M Jongen; W C J Hop; Gerhard H Visser; Bart C Jacobs; Pieter A Van Doorn
Pain in Guillain-Barre syndrome: a long-term follow-up study.
Neurology 2010;75(16):1439-47.
2010: E A Cats; W-Ludo van der Pol; Sanne Piepers; Hessel Franssen; Bart C Jacobs; Renske M Van den Berg-Vos; J B M Kuks; Pieter A Van Doorn; B G M van Engelen; J J Verschuuren; J H J Wokke; Jan Veldink; Leonard H Van den Berg
Correlates of outcome and response to IVIg in 88 patients with multifocal motor neuropathy.
Neurology 2010;75(9):818-25.
2010: Mark L Kuijf; Janneke N Samsom; Wouter Van Rijs; Marieke Bax; Ruth Huizinga; Astrid Heikema; Pieter A Van Doorn; Alex Van Belkum; Yvette van Kooyk; Peter C Burgers; Theo M Luider; Hubert P Endtz; Edward E S Nieuwenhuis; Bart C Jacobs
TLR4-mediated sensing of Campylobacter jejuni by dendritic cells is determined by sialylation.
Journal of immunology (Baltimore, Md. : 1950) 2010;185(1):748-55.
2010: Christa Walgaard; Hester Floor Lingsma; Liselotte Ruts; Judith Drenthen; Rinske van Koningsveld; Marcel J P Garssen; Pieter A Van Doorn; Ewout W Steyerberg; Bart C Jacobs
Prediction of respiratory insufficiency in Guillain-Barré syndrome.
Annals of neurology 2010;67(6):781-7.
2010: Liselotte Ruts; J Drenthen; Bart C Jacobs; Pieter A Van Doorn
Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: a prospective study.
Neurology 2010;74(21):1680-6.
2010: Pieter A Van Doorn; Krista Kuitwaard; Christa Walgaard; Rinske van Koningsveld; Liselotte Ruts; Bart C Jacobs
IVIG treatment and prognosis in Guillain-Barré syndrome.
Journal of clinical immunology 2010;30 Suppl 1():S74-8.
2010: J M de Vries; M L C Hagemans; J B J Bussmann; A T van der Ploeg; Pieter A Van Doorn
Fatigue in neuromuscular disorders: focus on Guillain-Barré syndrome and Pompe disease.
Cellular and molecular life sciences : CMLS 2010;67(5):701-13.
2010: Mohamed Mahdi-Rogers; Anthony V Swan; Pieter A Van Doorn; Richard Ac Hughes
Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy.
Cochrane database of systematic reviews (Online) 2010;(11):CD003280.
2010: C Wim Ang; Jeroen R Dijkstra; Marcel A de Klerk; Hubert P Endtz; Pieter A Van Doorn; Bart C Jacobs; Suzan H M Jeurissen; Jaap A Wagenaar
Host factors determine anti-GM1 response following oral challenge of chickens with Guillain-Barré syndrome derived Campylobacter jejuni strain GB11.
PloS one 2010;5(3):e9820.
2009: Krista Kuitwaard; Martine E Bos-Eyssen; Patricia H Blomkwist-Markens; Pieter A Van Doorn
Recurrences, vaccinations and long-term symptoms in GBS and CIDP.
Journal of the peripheral nervous system : JPNS 2009;14(4):310-5.
2009: Sonja I van Nes; Els K Vanhoutte; Catharina G Faber; Marcel Garssen; Pieter A Van Doorn; I S J Merkies
Improving fatigue assessment in immune-mediated neuropathies: the modified Rasch-built fatigue severity scale.
Journal of the peripheral nervous system : JPNS 2009;14(4):268-78.
2009: Krista Kuitwaard; Jenny de Gelder; Anne P Tio-Gillen; Wim C J Hop; Teun van Gelder; Albert W van Toorenenbergen; Pieter A Van Doorn; Bart C Jacobs
Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barré syndrome.
Annals of neurology 2009;66(5):597-603.
2009: Mark L Kuijf; M Eurelings; Anne P Tio-Gillen; Pieter A Van Doorn; Leonard H Van den Berg; Herbert Hooijkaas; J Stork; N C Notermans; Bart C Jacobs
Detection of anti-MAG antibodies in polyneuropathy associated with IgM monoclonal gammopathy.
Neurology 2009;73(9):688-95.
2009: Marieke J H J Dekker; Erica L T van den Akker; Jan W Koper; Laura Manenschijn; Karin Geleijns; Liselotte Ruts; Wouter Van Rijs; Anne P Tio-Gillen; Pieter A Van Doorn; Steven W J Lamberts; Bart C Jacobs
Effect of glucocorticoid receptor gene polymorphisms in Guillain-Barré syndrome.
Journal of the peripheral nervous system : JPNS 2009;14(2):75-83.
2009: Pieter A Van Doorn
What's new in Guillain-Barré syndrome in 2007-2008?
Journal of the peripheral nervous system : JPNS 2009;14(2):72-4.
2009: Krista Kuitwaard; Pieter A Van Doorn
Newer therapeutic options for chronic inflammatory demyelinating polyradiculoneuropathy.
Drugs 2009;69(8):987-1001.
2009: I S J Merkies; Vera Bril; M C Dalakas; C Deng; P Donofrio; K Hanna; H-P Hartung; R A C Hughes; N Latov; Pieter A Van Doorn
Health-related quality-of-life improvements in CIDP with immune globulin IV 10%: the ICE Study.
Neurology 2009;72(15):1337-44.
2009: Frans Brugman; Jan Veldink; Hessel Franssen; Marianne De Visser; J M B V de Jong; Carin G Faber; Berry H P Kremer; H Jurgen Schelhaas; Pieter A Van Doorn; Jan J G M Verschuuren; Richard P M Bruyn; Jan B M Kuks; Wim Robberecht; J H J Wokke; Leonard H Van den Berg
Differentiation of hereditary spastic paraparesis from primary lateral sclerosis in sporadic adult-onset upper motor neuron syndromes.
Archives of neurology 2009;66(4):509-14.
2009: N A M E Van der Beek; M L C Hagemans; Arnold J J Reuser; W C J Hop; Ans T Van Der Ploeg; Pieter A Van Doorn; J H J Wokke
Rate of disease progression during long-term follow-up of patients with late-onset Pompe disease.
Neuromuscular disorders : NMD 2009;19(2):113-7.
2009: Mark L Kuijf; Liselotte Ruts; Pieter A Van Doorn; Peter J Koudstaal; Bart C Jacobs
Diagnostic value of anti-GQ1b antibodies in a patient with relapsing dysarthria and ataxia.
BMJ case reports 2009;2009():.
2008: Mark L Kuijf; Karin Geleijns; Noureddine Ennaji; Wouter Van Rijs; Pieter A Van Doorn; Bart C Jacobs
Susceptibility to Guillain-Barré syndrome is not associated with CD1A and CD1E gene polymorphisms.
Journal of neuroimmunology 2008;205(1-2):110-2.
2008: N A M E van der Beek; Osama Soliman; C I van Capelle; Marcel L Geleijnse; Wim B Vletter; Marian A Kroos; Arnold J J Reuser; Ingrid M E Frohn-Mulder; Pieter A Van Doorn; Ans T Van Der Ploeg
Cardiac evaluation in children and adults with Pompe disease sharing the common c.-32-13T>G genotype rarely reveals abnormalities.
Journal of the neurological sciences 2008;275(1-2):46-50.
2008: Liselotte Ruts; Roberto Rico; Rinske van Koningsveld; Juan D Botero; Jan Meulstee; Izzy Gerstenbluth; Ingemar S J Merkies; Pieter A Van Doorn
Pain accompanies pure motor Guillain-Barré syndrome.
Journal of the peripheral nervous system : JPNS 2008;13(4):305-6.
2008: Pieter A Van Doorn; Liselotte Ruts; Bart C Jacobs
Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome.
Lancet neurology 2008;7(10):939-50.
2008: Pieter A Van Doorn; I S J Merkies
How to assess new drugs for neuropathies: advances in trial design and methodology.
Current opinion in neurology 2008;21(5):519-26.
2008: Osama Soliman; N A M E van der Beek; Pieter A Van Doorn; Wim B Vletter; Attila Nemes; B M Van Dalen; Folkert J Ten Cate; Ans T Van Der Ploeg; Marcel L Geleijnse
Cardiac involvement in adults with Pompe disease.
Journal of internal medicine 2008;264(4):333-9.
2008: S I van Nes; C G Faber; R M T P Hamers; O Harschnitz; M Bakkers; M C E Hermans; R J Meijer; Pieter A Van Doorn; I S J Merkies
Revising two-point discrimination assessment in normal aging and in patients with polyneuropathies.
Journal of neurology, neurosurgery, and psychiatry 2008;79(7):832-4.
2008: C I van Capelle; L P F Winkel; M L C Hagemans; S K Shapira; W F M Arts; Pieter A Van Doorn; W C J Hop; Arnold J J Reuser; Ans T Van Der Ploeg
Eight years experience with enzyme replacement therapy in two children and one adult with Pompe disease.
Neuromuscular disorders : NMD 2008;18(6):447-52.
2008: Richard A C Hughes; Peter Donofrio; Vera Bril; Marinos C Dalakas; Chunqin Deng; Kim Hanna; Hans-Peter Hartung; Norman Latov; Ingemar S J Merkies; Pieter A Van Doorn
Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial.
Lancet neurology 2008;7(2):136-44.
2008: Bart C Jacobs; Michiaki Koga; Wouter Van Rijs; Karin Geleijns; Pieter A Van Doorn; Hugh J Willison; Nobuhiro Yuki
Subclass IgG to motor gangliosides related to infection and clinical course in Guillain-Barré syndrome.
Journal of neuroimmunology 2008;194(1-2):181-90.
2008: Liesbeth S Smit; Daniella Roofthooft; Fred van Ruissen; Frank Baas; Pieter A Van Doorn
Congenital hypomyelinating neuropathy, a long term follow-up study in an affected family.
Neuromuscular disorders : NMD 2008;18(1):59-62.
2007: Liselotte Ruts; Pieter A Van Doorn; Jeroen P Blankevoort; Errol P Prens
Transient hypertrichosis in a patient with Guillain-Barré syndrome.
Journal of the peripheral nervous system : JPNS 2007;12(4):290-2.
2007: Karin Geleijns; Marieke Emonts; Jon D Laman; Wouter Van Rijs; Pieter A Van Doorn; Peter W M Hermans; Bart C Jacobs
Genetic polymorphisms of macrophage-mediators in Guillain-Barré syndrome.
Journal of neuroimmunology 2007;190(1-2):127-30.
2007: Liselotte Ruts; Rinske van Koningsveld; Bart C Jacobs; Pieter A Van Doorn
Determination of pain and response to methylprednisolone in Guillain-Barré syndrome.
Journal of neurology 2007;254(10):1318-22.
2007: Marcel P J Garssen; Rinske van Koningsveld; Pieter A Van Doorn; I S J Merkies; M Scheltens-de Boer; J A van Leusden; Ivo van Schaik; W H J P Linssen; F Visscher; A M Boon; C G Faber; J Meulstee; M J J Prick; Leonard H Van den Berg; Hessel Franssen; J A P Hiel; P Y K Van Den Bergh; C J M Sindic
Treatment of Guillain-Barré syndrome with mycophenolate mofetil: a pilot study.
Journal of neurology, neurosurgery, and psychiatry 2007;78(9):1012-3.
2007: Richard AC Hughes; Anthony V Swan; Jean-Claude Raphaël; Djillali Annane; Rinske van Koningsveld; Pieter A Van Doorn
Immunotherapy for Guillain-Barré syndrome: a systematic review.
Brain : a journal of neurology 2007;130(Pt 9):2245-57.
2007: Mark L Kuijf; Peggy C R Godschalk; Michel Gilbert; Hubert P Endtz; Anne P Tio-Gillen; C Wim Ang; Pieter A Van Doorn; Bart C Jacobs
Origin of ganglioside complex antibodies in Guillain-Barré syndrome.
Journal of neuroimmunology 2007;188(1-2):69-73.
2007: Rinske van Koningsveld; Ewout W Steyerberg; Richard AC Hughes; Anthony V Swan; Pieter A Van Doorn; Bart C Jacobs
A clinical prognostic scoring system for Guillain-Barré syndrome.
Lancet neurology 2007;6(7):589-94.
2007: M L C Hagemans; P Laforêt; W J C Hop; I S J Merkies; Pieter A Van Doorn; Arnold J J Reuser; Ans T Van Der Ploeg
Impact of late-onset Pompe disease on participation in daily life activities: evaluation of the Rotterdam Handicap Scale.
Neuromuscular disorders : NMD 2007;17(7):537-43.
2007: M L C Hagemans; Sabine P M van Schie; A Cecile J W Janssens; Pieter A Van Doorn; Arnold J J Reuser; Ans T Van Der Ploeg
Fatigue: an important feature of late-onset Pompe disease.
Journal of neurology 2007;254(7):941-5.
2007: Marcel P J Garssen; Maartje L Schillings; Pieter A Van Doorn; B G M van Engelen; Machiel J Zwarts
Contribution of central and peripheral factors to residual fatigue in Guillain-Barré syndrome.
Muscle & nerve 2007;36(1):93-9.
2007: Maarten C de Rijk; Frederique H Vermeij; Maartje Suntjens; Pieter A Van Doorn
Does a carpal tunnel syndrome predict an underlying disease?
Journal of neurology, neurosurgery, and psychiatry 2007;78(6):635-7.
2007: Harro Seelaar; H Jurgen Schelhaas; Asma Azmani; Benno Küsters; Sonia M Rosso; Danielle Majoor-Krakauer; Patrizia Rizzu; Ming ten Brummelhuis; Pieter A Van Doorn; Wouter Kamphorst; Rob Willemsen; Maarten C de Rijk; John C van Swieten
TDP-43 pathology in familial frontotemporal dementia and motor neuron disease without Progranulin mutations.
Brain : a journal of neurology 2007;130(Pt 5):1375-85.
2007: J B J Bussmann; Marcel P J Garssen; Pieter A Van Doorn; Henk J Stam
Analysing the favourable effects of physical exercise: relationships between physical fitness, fatigue and functioning in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy.
Journal of rehabilitation medicine : official journal of the UEMS European Board of Physical and Rehabilitation Medicine 2007;39(2):121-5.
2007: B G M van Engelen; H van Veenendaal; Pieter A Van Doorn; C G Faber; J H van der Hoeven; N G Janssen; Nicolette C Notermans; Ivo van Schaik; LH Visser; Jan J Verschuuren
The Dutch neuromuscular database CRAMP (Computer Registry of All Myopathies and Polyneuropathies): development and preliminary data.
Neuromuscular disorders : NMD 2007;17(1):33-7.
2006: A Cecile J W Janssens; Dragan Buljevac; Pieter A Van Doorn; F G A Van der Meché; C H Polman; Jan Passchier; Rogier Q Hintzen
Prediction of anxiety and distress following diagnosis of multiple sclerosis: a two-year longitudinal study.
Multiple sclerosis (Houndmills, Basingstoke, England) 2006;12(6):794-801.
2006: Karin Geleijns; Anja Roos; Jeanine J Houwing-Duistermaat; Wouter Van Rijs; Anne P Tio-Gillen; Jon D Laman; Pieter A Van Doorn; Bart C Jacobs
Mannose-binding lectin contributes to the severity of Guillain-Barré syndrome.
Journal of immunology (Baltimore, Md. : 1950) 2006;177(6):4211-7.
2006: Marcel P J Garssen; Rinske van Koningsveld; Pieter A Van Doorn
Residual fatigue is independent of antecedent events and disease severity in Guillain-Barré syndrome.
Journal of neurology 2006;253(9):1143-6.
2006: R D M Hadden; Eduardo Nobile-Orazio; Claudia Sommer; A Hahn; Isabel Illa; E Morra; J Pollard; Richard AC Hughes; Pierre Bouche; David R Cornblath; E M A Evers; Carol Lee Koski; Jean-Marc Léger; P Y K Van Den Bergh; Pieter A Van Doorn; Ivo van Schaik
European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of paraproteinaemic demyelinating neuropathies: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society.
European journal of neurology : the official journal of the European Federation of Neurological Societies 2006;13(8):809-18.
2006: Ivo van Schaik; Pierre Bouche; Isabel Illa; Jean-Marc Léger; P Y K Van Den Bergh; David R Cornblath; E M A Evers; R D M Hadden; Richard AC Hughes; Carol Lee Koski; Eduardo Nobile-Orazio; J Pollard; Claudia Sommer; Pieter A Van Doorn
European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy.
European journal of neurology : the official journal of the European Federation of Neurological Societies 2006;13(8):802-8.
2006: Marcel P J Garssen; Pieter A Van Doorn; Gerhard H Visser
Nerve conduction studies in relation to residual fatigue in Guillain-Barré syndrome.
Journal of neurology 2006;253(7):851-6.
2006: N A M E van der Beek; M L C Hagemans; Ans T Van Der Ploeg; Arnold J J Reuser; Pieter A Van Doorn
Pompe disease (glycogen storage disease type II): clinical features and enzyme replacement therapy.
Acta neurologica Belgica 2006;106(2):82-6.
2006: Mark L Kuijf; C Wim Ang; Pieter A Van Doorn; Hubert G M Niesters; Bart C Jacobs
Presence or absence of cytomegalovirus in cerebrospinal fluid from patients with Guillain-Barré syndrome?
The Journal of infectious diseases 2006;193(10):1471-2; author reply 1472-3.
2006: Richard AC Hughes; Pierre Bouche; David R Cornblath; E M A Evers; R D M Hadden; A Hahn; Isabel Illa; Carol Lee Koski; Jean-Marc Léger; Eduardo Nobile-Orazio; J Pollard; Claudia Sommer; P Y K Van Den Bergh; Pieter A Van Doorn; Ivo van Schaik
European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society.
European journal of neurology : the official journal of the European Federation of Neurological Societies 2006;13(4):326-32.
2006: M L C Hagemans; W J C Hop; Pieter A Van Doorn; Arnold J J Reuser; Ans T Van Der Ploeg
Course of disability and respiratory function in untreated late-onset Pompe disease.
Neurology 2006;66(4):581-3.
2006: Marcel P J Garssen; Joleen Blok; Pieter A Van Doorn; Gerhard H Visser
Conduction velocity distribution in neurologically well-recovered but fatigued Guillain-Barré syndrome patients.
Muscle & nerve 2006;33(2):177-82.
2006: Richard AC Hughes; Anthony V Swan; Rinske van Koningsveld; Pieter A Van Doorn
Corticosteroids for Guillain-Barré syndrome.
Cochrane database of systematic reviews (Online) 2006;(2):CD001446.
2006: Richard AC Hughes; Jean-Claude Raphaël; A V Swan; Pieter A Van Doorn
Intravenous immunoglobulin for Guillain-Barré syndrome.
Cochrane database of systematic reviews (Online) 2006;(1):CD002063.
2006: Marcel P J Garssen; P I M Schmitz; I S J Merkies; Bart C Jacobs; F G A Van der Meché; Pieter A Van Doorn
Amantadine for treatment of fatigue in Guillain-Barre syndrome: a randomised, double blind, placebo controlled, crossover trial.
Journal of neurology, neurosurgery, and psychiatry 2006;77(1):61-5.
2006: J P A Samijn; P A W te Boekhorst; Tjeerd Mondria; Pieter A Van Doorn; H Zwenneke Flach; F G A Van der Meché; J Cornelissen; Wim C J Hop; Bob Löwenberg; Rogier Q Hintzen
Intense T cell depletion followed by autologous bone marrow transplantation for severe multiple sclerosis.
Journal of neurology, neurosurgery, and psychiatry 2006;77(1):46-50.
2005: Mark L Kuijf; Pieter A Van Doorn; Anne P Tio-Gillen; Karin Geleijns; C Wim Ang; Herbert Hooijkaas; Wim C J Hop; Bart C Jacobs
Diagnostic value of anti-GM1 ganglioside serology and validation of the INCAT-ELISA.
Journal of the neurological sciences 2005;239(1):37-44.
2005: Umesh A Badrising; Marion L C Maat-Schieman; Johannes C van Houwelingen; Pieter A Van Doorn; Sjoerd G van Duinen; B G M van Engelen; Carin G Faber; Jessica E Hoogendijk; Aeiko E de Jager; Peter J Koehler; Marianne De Visser; Jan J Verschuuren; Axel R Wintzen
Inclusion body myositis. Clinical features and clinical course of the disease in 64 patients.
Journal of neurology 2005;252(12):1448-54.
2005: Dragan Buljevac; G J J van Doornum; H Zwenneke Flach; J Groen; A D M E Osterhaus; Wim C J Hop; Pieter A Van Doorn; F G A Van der Meché; Rogier Q Hintzen
Epstein-Barr virus and disease activity in multiple sclerosis.
Journal of neurology, neurosurgery, and psychiatry 2005;76(10):1377-81.
2005: Léon P F Winkel; M L C Hagemans; Pieter A Van Doorn; M Christa B Loonen; Wim J C Hop; Arnold J J Reuser; Ans T Van Der Ploeg
The natural course of non-classic Pompe's disease; a review of 225 published cases.
Journal of neurology 2005;252(8):875-84.
2005: Liselotte Ruts; Rinske van Koningsveld; Pieter A Van Doorn
Distinguishing acute-onset CIDP from Guillain-Barré syndrome with treatment related fluctuations.
Neurology 2005;65(1):138-40.
2005: M L C Hagemans; Léon P F Winkel; W C J Hop; Arnold J J Reuser; Pieter A Van Doorn; Ans T Van Der Ploeg
Disease severity in children and adults with Pompe disease related to age and disease duration.
Neurology 2005;64(12):2139-41.
2005: Pieter A Van Doorn
Treatment of Guillain-Barré syndrome and CIDP.
Journal of the peripheral nervous system : JPNS 2005;10(2):113-27.
2005: Nina M van Sorge; W-Ludo van der Pol; Marc D Jansen; Karin Geleijns; Sandra Kalmijn; Richard AC Hughes; Jeremy H Rees; Jane Pritchard; Christian A Vedeler; Kjell-Morten Myhr; Chris Shaw; Ivo van Schaik; J H J Wokke; Pieter A Van Doorn; Bart C Jacobs; Jan G J van de Winkel; Leonard H Van den Berg
Severity of Guillain-Barré syndrome is associated with Fc gamma Receptor III polymorphisms.
Journal of neuroimmunology 2005;162(1-2):157-64.
2005: Karin Geleijns; Jon D Laman; Wouter Van Rijs; Anne P Tio-Gillen; Rogier Q Hintzen; Pieter A Van Doorn; Bart C Jacobs
Fas polymorphisms are associated with the presence of anti-ganglioside antibodies in Guillain-Barre syndrome.
Journal of neuroimmunology 2005;161(1-2):183-9.
2005: M L C Hagemans; Léon P F Winkel; Pieter A Van Doorn; W J C Hop; M Christa B Loonen; Arnold J J Reuser; Ans T Van Der Ploeg
Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients.
Brain : a journal of neurology 2005;128(Pt 3):671-7.
2005: Karin Geleijns; G M Th Schreuder; Bart C Jacobs; Kees Sintnicolaas; Rinske van Koningsveld; J Meulstee; Jon D Laman; Pieter A Van Doorn
HLA class II alleles are not a general susceptibility factor in Guillain-Barré syndrome.
Neurology 2005;64(1):44-9.
2004: Umesh A Badrising; G M Th Schreuder; Marius J Giphart; Karin Geleijns; Jan J Verschuuren; Axel R Wintzen; Marion L C Maat-Schieman; Pieter A Van Doorn; B G M van Engelen; Carin G Faber; Jessica E Hoogendijk; Aeiko E de Jager; Peter J Koehler; Marianne De Visser; Sjoerd G van Duinen
Associations with autoimmune disorders and HLA class I and II antigens in inclusion body myositis.
Neurology 2004;63(12):2396-8.
2004: Marcel P J Garssen; J B J Bussmann; P I M Schmitz; A Zandbergen; T G Welter; I S J Merkies; Henk J Stam; Pieter A Van Doorn
Physical training and fatigue, fitness, and quality of life in Guillain-Barré syndrome and CIDP.
Neurology 2004;63(12):2393-5.
2004: Karin Geleijns; B A Brouwer; Bart C Jacobs; Jeanine J Houwing-Duistermaat; C.M. Duijn; Pieter A Van Doorn
The occurrence of Guillain-Barre syndrome within families.
Neurology 2004;63(9):1747-50.
2004: M L C Hagemans; A Cecile J W Janssens; Léon P F Winkel; K A Sieradzan; Arnold J J Reuser; Pieter A Van Doorn; Ans T Van Der Ploeg
Late-onset Pompe disease primarily affects quality of life in physical health domains.
Neurology 2004;63(9):1688-92.
2004: Pieter A Van Doorn; Liselotte Ruts
Treatment of chronic inflammatory demyelinating polyneuropathy.
Current opinion in neurology 2004;17(5):607-13.
2004: I S J Merkies; P I M Schmitz; Pieter A Van Doorn
Sensory exam with a quantitative tuning fork: rapid, sensitive and predictive of SNAP amplitude.
Neurology 2004;63(6):1138; author reply 1138.
2004: Paul W Wirtz; J Gert van Dijk; Pieter A Van Doorn; B G M van Engelen; Anneke J van der Kooi; J B M Kuks; Albert Twijnstra; Marianne De Visser; LH Visser; J H J Wokke; Axel R Wintzen; Jan J Verschuuren
The epidemiology of the Lambert-Eaton myasthenic syndrome in the Netherlands.
Neurology 2004;63(2):397-8.
2004: A Cecile J W Janssens; Josien B de Boer; Nynke F Kalkers; Jan Passchier; Pieter A Van Doorn; Rogier Q Hintzen
Patients with multiple sclerosis prefer early diagnosis.
European journal of neurology : the official journal of the European Federation of Neurological Societies 2004;11(5):335-7.
2004: Johanna M P Van den Hout; Joep H J Kamphoven; Léon P F Winkel; W F M Arts; J B C de Klerk; M Christa B Loonen; Arnold G Vulto; Adri Cromme-Dijkhuis; Nynke Weisglas-Kuperus; Wim Hop; Hans Van Hirtum; Otto P van Diggelen; Marijke A Boer; Marian A Kroos; Pieter A Van Doorn; Edwin Van der Voort; Barbara Sibbles; Emiel J J M Van Corven; Just P J Brakenhoff; Johan L K Van Hove; Jan A M Smeitink; Gerard de Jong; Arnold J J Reuser; Ans T Van Der Ploeg
Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk.
Pediatrics 2004;113(5):e448-57.
2004: Karin Geleijns; Bart C Jacobs; Wouter Van Rijs; Anne P Tio-Gillen; Jon D Laman; Pieter A Van Doorn
Functional polymorphisms in LPS receptors CD14 and TLR4 are not associated with disease susceptibility or Campylobacter jejuni infection in Guillain-Barré patients.
Journal of neuroimmunology 2004;150(1-2):132-8.
2004: Léon P F Winkel; Johanna M P Van den Hout; Joep H J Kamphoven; Janus A M Disseldorp; Maaike Remmerswaal; W F M Arts; M Christa B Loonen; Arnold G Vulto; Pieter A Van Doorn; Gerard de Jong; Wim Hop; G Peter A Smit; Stuart K Shapira; Marijke A Boer; Otto P van Diggelen; Arnold J J Reuser; Ans T Van Der Ploeg
Enzyme replacement therapy in late-onset Pompe's disease: a three-year follow-up.
Annals of neurology 2004;55(4):495-502.
2004: A Cecile J W Janssens; Pieter A Van Doorn; Josien B de Boer; F G A Van der Meché; Jan Passchier; Rogier Q Hintzen
Perception of prognostic risk in patients with multiple sclerosis: the relationship with anxiety, depression, and disease-related distress.
Journal of clinical epidemiology 2004;57(2):180-6.
2004: Pieter A Van Doorn; Rinske van Koningsveld
Immunotherapy for Guillain-Barré syndrome.
Lancet neurology 2004;3(2):84.
2004: Rinske van Koningsveld; P I M Schmitz; F G Avander Meché; Leo H Visser; J Meulstee; Pieter A Van Doorn
Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial.
Lancet 2004;363(9404):192-6.
2004: Richard AC Hughes; Anthony V Swan; Pieter A Van Doorn
Cytotoxic drugs and interferons for chronic inflammatory demyelinating polyradiculoneuropathy.
Cochrane database of systematic reviews (Online) 2004;(4):CD003280.
2003: Dragan Buljevac; Roel P Verkooyen; Bart C Jacobs; Wim Hop; Liesbeth A van der Zwaan; Pieter A Van Doorn; Rogier Q Hintzen
Chlamydia pneumoniae and the risk for exacerbation in multiple sclerosis patients.
Annals of neurology 2003;54(6):828-31.
2003: A Cecile J W Janssens; Pieter A Van Doorn; Josien B de Boer; F G A Van der Meché; Jan Passchier; Rogier Q Hintzen
Impact of recently diagnosed multiple sclerosis on quality of life, anxiety, depression and distress of patients and partners.
Acta neurologica Scandinavica 2003;108(6):389-95.
2003: Dragan Buljevac; W C J Hop; W Reedeker; A Cecile J W Janssens; F G A Van der Meché; Pieter A Van Doorn; Rogier Q Hintzen
Self reported stressful life events and exacerbations in multiple sclerosis: prospective study.
BMJ (Clinical research ed.) 2003;327(7416):646.
2003: A Cecile J W Janssens; Pieter A Van Doorn; Josien B de Boer; Nynke F Kalkers; F G A van der Meche; Jan Passchier; Rogier Q Hintzen
Anxiety and depression influence the relation between disability status and quality of life in multiple sclerosis.
Multiple sclerosis (Houndmills, Basingstoke, England) 2003;9(4):397-403.
2003: I S J Merkies; P I M Schmitz; F G A Van der Meché; Pieter A Van Doorn
Comparison between impairment and disability scales in immune-mediated polyneuropathies.
Muscle & nerve 2003;28(1):93-100.
2003: Léon P F Winkel; Joep H J Kamphoven; Hannerieke J M P Van Den Hout; Lies A Severijnen; Pieter A Van Doorn; Arnold J J Reuser; Ans T Van Der Ploeg
Morphological changes in muscle tissue of patients with infantile Pompe's disease receiving enzyme replacement therapy.
Muscle & nerve 2003;27(6):743-51.
2003: A Cecile J W Janssens; Josien B de Boer; Pieter A Van Doorn; H M van ver Ploeg; F G A van ver Meché; Jan Passchier; Rogier Q Hintzen
Expectations of wheelchair-dependency in recently diagnosed patients with multiple sclerosis and their partners.
European journal of neurology : the official journal of the European Federation of Neurological Societies 2003;10(3):287-93.
2003: Nina M van Sorge; Leonard H Van den Berg; Karin Geleijns; Jos van Strijp; Bart C Jacobs; Pieter A Van Doorn; J H J Wokke; Jan G J van de Winkel; Jeanette Leusen; W-Ludo van der Pol
Anti-GM1 IgG antibodies induce leukocyte effector functions via Fcgamma receptors.
Annals of neurology 2003;53(5):570-9.
2003: Sebastiaan Overeem; Karin Geleijns; Marcel P J Garssen; Bart C Jacobs; Pieter A Van Doorn; Gert Jan Lammers
Screening for anti-ganglioside antibodies in hypocretin-deficient human narcolepsy.
Neuroscience letters 2003;341(1):13-6.
2003: Richard AC Hughes; Anthony V Swan; Pieter A Van Doorn
Cytotoxic drugs and interferons for chronic inflammatory demyelinating polyradiculoneuropathy.
Cochrane database of systematic reviews (Online) 2003;(1):CD003280.
2003: I S J Merkies; P I M Schmitz; F G A Van der Meché; J P A Samijn; Pieter A Van Doorn
Connecting impairment, disability, and handicap in immune mediated polyneuropathies.
Journal of neurology, neurosurgery, and psychiatry 2003;74(1):99-104.
2002: Paul W Wirtz; M Sotodeh; M Nijnuis; Pieter A Van Doorn; B G M van Engelen; Rogier Q Hintzen; P L M De Kort; J B M Kuks; Albert Twijnstra; Marianne De Visser; LH Visser; J H J Wokke; Axel R Wintzen; Jan J Verschuuren
Difference in distribution of muscle weakness between myasthenia gravis and the Lambert-Eaton myasthenic syndrome.
Journal of neurology, neurosurgery, and psychiatry 2002;73(6):766-8.
2002: Pieter A Van Doorn; Marcel P J Garssen
Treatment of immune neuropathies.
Current opinion in neurology 2002;15(5):623-31.
2002: C Wim Ang; Anne P Tio-Gillen; J Groen; Paul Herbrink; Bart C Jacobs; Rinske van Koningsveld; A D M E Osterhaus; F G A Van der Meché; Pieter A Van Doorn
Cross-reactive anti-galactocerebroside antibodies and Mycoplasma pneumoniae infections in Guillain-Barré syndrome.
Journal of neuroimmunology 2002;130(1-2):179-83.
2002: C Wim Ang; Peter G Noordzij; Marry de Klerk; Hubert P Endtz; Pieter A Van Doorn; Jon D Laman
Ganglioside mimicry of Campylobacter jejuni lipopolysaccharides determines antiganglioside specificity in rabbits.
Infection and immunity 2002;70(9):5081-5.
2002: I S J Merkies; P I M Schmitz; F G A Van der Meché; J P A Samijn; Pieter A Van Doorn
Quality of life complements traditional outcome measures in immune-mediated polyneuropathies.
Neurology 2002;59(1):84-91.
2002: I S J Merkies; P I M Schmitz; F G A Van der Meché; J P A Samijn; Pieter A Van Doorn
Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies.
Journal of neurology, neurosurgery, and psychiatry 2002;72(5):596-601.
2002: Dragan Buljevac; H Zwenneke Flach; W C J Hop; Daniëlle Hijdra; Jon D Laman; Huub F J Savelkoul; F G A Van der Meché; Pieter A Van Doorn; Rogier Q Hintzen
Prospective study on the relationship between infections and multiple sclerosis exacerbations.
Brain : a journal of neurology 2002;125(Pt 5):952-60.
2002: Umesh A Badrising; Marion L C Maat-Schieman; Michel D Ferrari; Aeilko H Zwinderman; Judith A M Wessels; Ferdinand C Breedveld; Pieter A Van Doorn; B G M van Engelen; Jessica E Hoogendijk; Chris J Höweler; Aeiko E de Jager; F G I Jennekens; Peter J Koehler; Marianne De Visser; Alain Viddeleer; Jan J Verschuuren; Axel R Wintzen
Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo.
Annals of neurology 2002;51(3):369-72.
2002: I S J Merkies; P I M Schmitz; F G A Van der Meché; J P A Samijn; Pieter A Van Doorn
Psychometric evaluation of a new handicap scale in immune-mediated polyneuropathies.
Muscle & nerve 2002;25(3):370-7.
2002: C Wim Ang; Jon D Laman; Hugh J Willison; Eric R Wagner; Hubert P Endtz; Marry de Klerk; Anne P Tio-Gillen; Nicole van den Braak; Bart C Jacobs; Pieter A Van Doorn
Structure of Campylobacter jejuni lipopolysaccharides determines antiganglioside specificity and clinical features of Guillain-Barré and Miller Fisher patients.
Infection and immunity 2002;70(3):1202-8.
2002: Rinske van Koningsveld; P I M Schmitz; C Wim Ang; J Groen; A D M E Osterhaus; F G A Van der Meché; Pieter A Van Doorn
Infections and course of disease in mild forms of Guillain-Barré syndrome.
Neurology 2002;58(4):610-4.
2001: C Wim Ang; M Koga; Bart C Jacobs; Nobuhiro Yuki; F G A Van der Meché; Pieter A Van Doorn
Differential immune response to gangliosides in Guillain-Barré syndrome patients from Japan and The Netherlands.
Journal of neuroimmunology 2001;121(1-2):83-7.
2001: Marijke Eurelings; C Wim Ang; Nicolette C Notermans; Pieter A Van Doorn; Bart C Jacobs; Leonard H Van den Berg
Antiganglioside antibodies in polyneuropathy associated with monoclonal gammopathy.
Neurology 2001;57(10):1909-12.
2001: Rhidian Hughes; S Bensa; Hugh J Willison; P Y K Van Den Bergh; Giancarlo Comi; Isabel Illa; Eduardo Nobile-Orazio; Pieter A Van Doorn; Marinos C Dalakas; Martin Bojar; Anthony V Swan
Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy.
Annals of neurology 2001;50(2):195-201.
2001: Paul W Wirtz; Bart O Roep; G M Th Schreuder; Pieter A Van Doorn; B G M van Engelen; J B M Kuks; Albert Twijnstra; Marianne De Visser; LH Visser; J H J Wokke; Axel R Wintzen; Jan J Verschuuren
HLA class I and II in Lambert-Eaton myasthenic syndrome without associated tumor.
Human immunology 2001;62(8):809-13.
2001: Rinske van Koningsveld; R Rico; Izzy Gerstenbluth; P I M Schmitz; C Wim Ang; I S J Merkies; Bart C Jacobs; Yaskara Halabi; Hubert P Endtz; F G A Van der Meché; Pieter A Van Doorn
Gastroenteritis-associated Guillain-Barré syndrome on the Caribbean island Curaçao.
Neurology 2001;56(11):1467-72.
2001: Michiaki Koga; C Wim Ang; Nobuhiro Yuki; Bart C Jacobs; Paul Herbrink; F G A Van der Meché; Koichi Hirata; Pieter A Van Doorn
Comparative study of preceding Campylobacter jejuni infection in Guillain-Barré syndrome in Japan and The Netherlands.
Journal of neurology, neurosurgery, and psychiatry 2001;70(5):693-5.
2001: C Wim Ang; Marry de Klerk; Hubert P Endtz; Bart C Jacobs; Jon D Laman; F G A Van der Meché; Pieter A Van Doorn
Guillain-Barré syndrome- and Miller Fisher syndrome-associated Campylobacter jejuni lipopolysaccharides induce anti-GM1 and anti-GQ1b Antibodies in rabbits.
Infection and immunity 2001;69(4):2462-9.
2001: Rinske van Koningsveld; Pieter A Van Doorn; P I M Schmitz; F G A Van der Meché
Changes in referral pattern and its effect on outcome in patients with Guillain-Barré syndrome.
Neurology 2001;56(4):564-6.
2001: Richard AC Hughes; Jean-Claude Raphaël; Anthony V Swan; Pieter A Van Doorn
Intravenous immunoglobulin for Guillain-Barré syndrome.
Cochrane database of systematic reviews (Online) 2001;(2):CD002063.
2001: F G A Van der Meché; Pieter A Van Doorn; J Meulstee; F G Jennekens
Diagnostic and classification criteria for the Guillain-Barré syndrome.
European neurology 2001;45(3):133-9.
2000: Umesh A Badrising; Marion L C Maat-Schieman; Sjoerd G van Duinen; Ferdinand C Breedveld; Pieter A Van Doorn; B G M van Engelen; Frank van den Hoogen; Jessica E Hoogendijk; Chris J Höweler; Aeiko E de Jager; F G I Jennekens; Peter J Koehler; H van der Leeuw; Marianne De Visser; Jan J Verschuuren; Axel R Wintzen
Epidemiology of inclusion body myositis in the Netherlands: a nationwide study.
Neurology 2000;55(9):1385-7.
2000: C Wim Ang; Pieter A Van Doorn; Hubert P Endtz; I S J Merkies; Bart C Jacobs; Marry de Klerk; Rinske van Koningsveld; F G A Van der Meché
A case of Guillain-Barré syndrome following a family outbreak of Campylobacter jejuni enteritis.
Journal of neuroimmunology 2000;111(1-2):229-33.
2000: I S J Merkies; P I M Schmitz; J P A Samijn; F G Meché; Klaus V Toyka; Pieter A Van Doorn
Assessing grip strength in healthy individuals and patients with immune-mediated polyneuropathies.
Muscle & nerve 2000;23(9):1393-401.
2000: MA de Letter; Pieter A Van Doorn; H F Savelkoul; J D Laman; P I M Schmitz; A A Op de Coul; Leo H Visser; J M Kros; Johannes L J M Teepen; F G A Van der Meché
Critical illness polyneuropathy and myopathy (CIPNM): evidence for local immune activation by cytokine-expression in the muscle tissue.
Journal of neuroimmunology 2000;106(1-2):206-13.
2000: I S J Merkies; P I M Schmitz; F G A Van der Meché; Pieter A Van Doorn
Reliability and responsiveness of a graduated tuning fork in immune mediated polyneuropathies. The Inflammatory Neuropathy Cause and Treatment (INCAT) Group.
Journal of neurology, neurosurgery, and psychiatry 2000;68(5):669-71.
2000: C Wim Ang; Hubert P Endtz; Bart C Jacobs; Jon D Laman; Marry de Klerk; F G A Van der Meché; Pieter A Van Doorn
Campylobacter jejuni lipopolysaccharides from Guillain-Barré syndrome patients induce IgG anti-GM1 antibodies in rabbits.
Journal of neuroimmunology 2000;104(2):133-8.
2000: W L van der Pol; Leonard H Van den Berg; RH Scheepers; Johanna van der Bom; Pieter A Van Doorn; Rinske van Koningsveld; M C van den Broek; J H Wokke; Jan G J van de Winkel
IgG receptor IIa alleles determine susceptibility and severity of Guillain-Barré syndrome.
Neurology 2000;54(8):1661-5.
2000: Renske M Van den Berg-Vos; Leonard H Van den Berg; Hessel Franssen; Pieter A Van Doorn; I S J Merkies; J H J Wokke
Treatment of multifocal motor neuropathy with interferon-beta1A.
Neurology 2000;54(7):1518-21.
2000: C Wim Ang; Bart C Jacobs; AH Brandenburg; Jon D Laman; F G A Van der Meché; Albert D M E Osterhaus; Pieter A Van Doorn
Cross-reactive antibodies against GM2 and CMV-infected fibroblasts in Guillain-Barré syndrome.
Neurology 2000;54(7):1453-8.
2000: Nobuhiro Yuki; C Wim Ang; Michiaki Koga; Bart C Jacobs; Pieter A Van Doorn; Koichi Hirata; F G A Van der Meché
Clinical features and response to treatment in Guillain-Barré syndrome associated with antibodies to GM1b ganglioside.
Annals of neurology 2000;47(3):314-21.
2000: I S J Merkies; P I M Schmitz; F G A Van der Meché; Pieter A Van Doorn
Psychometric evaluation of a new sensory scale in immune-mediated polyneuropathies. Inflammatory Neuropathy Cause and Treatment (INCAT) Group.
Neurology 2000;54(4):943-9.
2000: Rinske van Koningsveld; Pieter A Van Doorn; P I M Schmitz; C Wim Ang; F G A Van der Meché
Mild forms of Guillain-Barré syndrome in an epidemiologic survey in The Netherlands.
Neurology 2000;54(3):620-5.
1999: C Wim Ang; Nobuhiro Yuki; Bart C Jacobs; M Koga; Pieter A Van Doorn; P I M Schmitz; F G A Van der Meché
Rapidly progressive, predominantly motor Guillain-Barré syndrome with anti-GalNAc-GD1a antibodies.
Neurology 1999;53(9):2122-7.
1999: M A Megens-de Letter; Leo H Visser; Pieter A Van Doorn; H F Savelkoul
Cytokines in the muscle tissue of idiopathic inflammatory myopathies: implications for immunopathogenesis and therapy.
European cytokine network 1999;10(4):471-8.
1999: I S J Merkies; P I M Schmitz; J P A Samijn; F G A Van der Meché; Pieter A Van Doorn
Fatigue in immune-mediated polyneuropathies. European Inflammatory Neuropathy Cause and Treatment (INCAT) Group.
Neurology 1999;53(8):1648-54.
1999: Leo H Visser; P I M Schmitz; J Meulstee; Pieter A Van Doorn; F G A Van der Meché
Prognostic factors of Guillain-Barré syndrome after intravenous immunoglobulin or plasma exchange. Dutch Guillain-Barré Study Group.
Neurology 1999;53(3):598-604.
1999: I S Martina; Pieter A Van Doorn; P I M Schmitz; J Meulstee; F G A Van der Meché
Chronic motor neuropathies: response to interferon-beta1a after failure of conventional therapies.
Journal of neurology, neurosurgery, and psychiatry 1999;66(2):197-201.
1999: Jaap J Plomp; Peter C Molenaar; Graham M O'Hanlon; Bart C Jacobs; Jean Veitch; M R Daha; Pieter A Van Doorn; F G van der Meché; Angela Vincent; B P Morgan; Hugh J Willison
Miller Fisher anti-GQ1b antibodies: alpha-latrotoxin-like effects on motor end plates.
Annals of neurology 1999;45(2):189-99.
1999: F G A Van der Meché; Pieter A Van Doorn
Chronic inflammatory demyelinating polyneuropathy (CIDP).
Electroencephalography and clinical neurophysiology. Supplement 1999;50():493-8.
1998: I S Martina; Rinske van Koningsveld; P I M Schmitz; F G A Van der Meché; Pieter A Van Doorn
Measuring vibration threshold with a graduated tuning fork in normal aging and in patients with polyneuropathy. European Inflammatory Neuropathy Cause and Treatment (INCAT) group.
Journal of neurology, neurosurgery, and psychiatry 1998;65(5):743-7.
1998: Bart C Jacobs; PH Rothbarth; F G A Van der Meché; Paul Herbrink; P I M Schmitz; Marry de Klerk; Pieter A Van Doorn
The spectrum of antecedent infections in Guillain-Barré syndrome: a case-control study.
Neurology 1998;51(4):1110-5.
1998: W H J P Linssen; Marianne De Visser; Nicolette C Notermans; J P Vreyling; Pieter A Van Doorn; J H J Wokke; F Baas; P A Bolhuis
Genetic heterogeneity in Miyoshi-type distal muscular dystrophy.
Neuromuscular disorders : NMD 1998;8(5):317-20.
1998: Leo H Visser; F G A Van der Meché; J Meulstee; Pieter A Van Doorn
Risk factors for treatment related clinical fluctuations in Guillain-Barré syndrome. Dutch Guillain-Barré study group.
Journal of neurology, neurosurgery, and psychiatry 1998;64(2):242-4.
1998: J L Jongen; Pieter A Van Doorn; F G A Van der Meché
High-dose intravenous immunoglobulin therapy for myasthenia gravis.
Journal of neurology 1998;245(1):26-31.
1997: Bart C Jacobs; Graham M O'Hanlon; E G Breedland; Jean Veitch; Pieter A Van Doorn; Hugh J Willison
Human IgM paraproteins demonstrate shared reactivity between Campylobacter jejuni lipopolysaccharides and human peripheral nerve disialylated gangliosides.
Journal of neuroimmunology 1997;80(1-2):23-30.
1997: F G A Van der Meché; Leo H Visser; Bart C Jacobs; Hubert P Endtz; J Meulstee; Pieter A Van Doorn
Guillain-Barré syndrome: multifactorial mechanisms versus defined subgroups.
The Journal of infectious diseases 1997;176 Suppl 2():S99-102.
1997: Nicolette C Notermans; Pieter A Van Doorn
[Polyneuropathy: diagnosis and management].
Nederlands tijdschrift voor geneeskunde 1997;141(48):2327-33.
1997: W H J P Linssen; Nicolette C Notermans; Y Van der Graaf; J H J Wokke; Pieter A Van Doorn; Chris J Höweler; H F Busch; Aeiko E de Jager; Marianne De Visser
Miyoshi-type distal muscular dystrophy. Clinical spectrum in 24 Dutch patients.
Brain : a journal of neurology 1997;120 ( Pt 11)():1989-96.
1997: Bart C Jacobs; Hubert P Endtz; F G A Van der Meché; MP Hazenberg; Marry de Klerk; Pieter A Van Doorn
Humoral immune response against Campylobacter jejuni lipopolysaccharides in Guillain-Barré and Miller Fisher syndrome.
Journal of neuroimmunology 1997;79(1):62-8.
1997: Bart C Jacobs; Pieter A Van Doorn; J H Groeneveld; Anne P Tio-Gillen; F G A Van der Meché
Cytomegalovirus infections and anti-GM2 antibodies in Guillain-Barré syndrome.
Journal of neurology, neurosurgery, and psychiatry 1997;62(6):641-3.
1997: J P Flipse; C S Straathof; Hans van der Steen; AF Van Leeuwen; Pieter A Van Doorn; F G A Van der Meché; H Collewijn
Binocular saccadic eye movements in multiple sclerosis.
Journal of the neurological sciences 1997;148(1):53-65.
1997: Bart C Jacobs; J Meulstee; Pieter A Van Doorn; F G A Van der Meché
Electrodiagnostic findings related to anti-GM1 and anti-GQ1b antibodies in Guillain-Barré syndrome.
Muscle & nerve 1997;20(4):446-52.
1997: J Meulstee; A Darbas; Pieter A Van Doorn; LJ van Briemen; F G A Van der Meché
Decreased electrical excitability of peripheral nerves in demyelinating polyneuropathies.
Journal of neurology, neurosurgery, and psychiatry 1997;62(4):398-400.
1997: Dylan Molenaar; Pieter A Van Doorn; Marinus Vermeulen
Pulsed high dose dexamethasone treatment in chronic inflammatory demyelinating polyneuropathy: a pilot study.
Journal of neurology, neurosurgery, and psychiatry 1997;62(4):388-90.
1997: Bart C Jacobs; MP Hazenberg; Pieter A Van Doorn; Hubert P Endtz; F G A Van der Meché
Cross-reactive antibodies against gangliosides and Campylobacter jejuni lipopolysaccharides in patients with Guillain-Barré or Miller Fisher syndrome.
The Journal of infectious diseases 1997;175(3):729-33.
1997: F G A Van der Meché; Pieter A Van Doorn
The current place of high-dose immunoglobulins in the treatment of neuromuscular disorders.
Muscle & nerve 1997;20(2):136-47.
1997: F G A Van der Meché; Pieter A Van Doorn
Future developments in the treatment of immune-mediated polyneuropathies.
European neurology 1997;38(3):230-7.
1996: Leo H Visser; F G A Van der Meché; J Meulstee; P P Rothbarth; Bart C Jacobs; P I M Schmitz; Pieter A Van Doorn
Cytomegalovirus infection and Guillain-Barré syndrome: the clinical, electrophysiologic, and prognostic features. Dutch Guillain-Barré Study Group.
Neurology 1996;47(3):668-73.
1996: Bart C Jacobs; Pieter A Van Doorn; P I M Schmitz; A P Tio-Gillen; Paul Herbrink; Leo H Visser; H Hooijkass; F G A Van der Meché
Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barré syndrome.
Annals of neurology 1996;40(2):181-7.
1996: I S Martina; Pieter A Van Doorn
Spinal cord compression due to extramedullary haematopoiesis in thalassaemia: a case report and review of the literature.
Journal of neurology 1996;243(4):364-6.
1995: F G A Van der Meché; Pieter A Van Doorn; Bart C Jacobs
Inflammatory neuropathies--pathogenesis and the role of intravenous immune globulin.
Journal of clinical immunology 1995;15(6 Suppl):63S-69S.
1995: Ivo van Schaik; M Vermeulen; Pieter A Van Doorn; Anneke Brand
Anti-beta-tubulin antibodies have no diagnostic value in patients with chronic inflammatory demyelinating polyneuropathy.
Journal of neurology 1995;242(9):599-603.
1995: Leo H Visser; F G A Van der Meché; Pieter A Van Doorn; J Meulstee; Bart C Jacobs; P G Oomes; R P Kleyweg; J Meulstee
Guillain-Barré syndrome without sensory loss (acute motor neuropathy). A subgroup with specific clinical, electrodiagnostic and laboratory features. Dutch Guillain-Barré Study Group.
Brain : a journal of neurology 1995;118 ( Pt 4)():841-7.
1995: F G A Van der Meché; Pieter A Van Doorn
Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy: immune mechanisms and update on current therapies.
Annals of neurology 1995;37 Suppl 1():S14-31.
1995: Bart C Jacobs; Hubert P Endtz; F G A Van der Meché; MP Hazenberg; H A Achtereekte; Pieter A Van Doorn
Serum anti-GQ1b IgG antibodies recognize surface epitopes on Campylobacter jejuni from patients with Miller Fisher syndrome.
Annals of neurology 1995;37(2):260-4.
1994: Pieter A Van Doorn
Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy.
Journal of neurology, neurosurgery, and psychiatry 1994;57 Suppl():38-42.
1994: Ivo van Schaik; M Vermeulen; Pieter A Van Doorn; Anneke Brand
Anti-GM1 antibodies in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) treated with intravenous immunoglobulin (IVIg).
Journal of neuroimmunology 1994;54(1-2):109-15.
1993: D A Breems; P W de Haas; F Visscher; L J Sabbe; H F M Busch; Pieter A Van Doorn
[Intravenously administered immunoglobulin first-choice remedy in autoimmune diseases?].
Nederlands tijdschrift voor geneeskunde 1993;137(45):2336.
1993: D A Breems; P W de Haas; F Visscher; L J Sabbe; H F M Busch; Pieter A Van Doorn
[Intravenously-administered immunoglobulins as first-choice agent in juvenile dermatomyositis].
Nederlands tijdschrift voor geneeskunde 1993;137(39):1979-82.
1993: I Lundkvist; Pieter A Van Doorn; M Vermeulen; Anneke Brand
Spontaneous recovery from the Guillain-Barré syndrome is associated with anti-idiotypic antibodies recognizing a cross-reactive idiotype on anti-neuroblastoma cell line antibodies.
Clinical immunology and immunopathology 1993;67(3 Pt 1):192-8.
1993: Marinus Vermeulen; Pieter A Van Doorn; A Brand; P F Strengers; F G Jennekens; H F M Busch
Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study.
Journal of neurology, neurosurgery, and psychiatry 1993;56(1):36-9.
1991: Pieter A Van Doorn; G M Schreuder; M Vermeulen; Joseph D'Amaro; A Brand
HLA antigens in patients with chronic inflammatory demyelinating polyneuropathy.
Journal of neuroimmunology 1991;32(2):133-9.
1991: Pieter A Van Doorn; M Vermeulen; A Brand; P G Mulder; H F M Busch
Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy. Clinical and laboratory characteristics associated with improvement.
Archives of neurology 1991;48(2):217-20.
1990: Pieter A Van Doorn; F Rossi; A Brand; M van Lint; M Vermeulen; M D Kazatchkine
On the mechanism of high-dose intravenous immunoglobulin treatment of patients with chronic inflammatory demyelinating polyneuropathy.
Journal of neuroimmunology 1990;29(1-3):57-64.
1990: Pieter A Van Doorn; A Brand; P F Strengers; J Meulstee; M Vermeulen
High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study.
Neurology 1990;40(2):209-12.
1990: Anneke Brand; Pieter A Van Doorn; F Rossi; M D Kazatchkine; M Vermeulen
The mechanism of action of intravenous immunoglobulin in patients with chronic inflammatory demyelinating polyneuropathy.
Progress in clinical and biological research 1990;337():405-9.
1989: I Lundkvist; Pieter A Van Doorn; M Vermeulen; M van Lint; Jon van Rood; Anneke Brand
Regulation of autoantibodies in inflammatory demyelinating polyneuropathy: spontaneous and therapeutic.
Immunological reviews 1989;110():105-17.